Metreleptin

3 trials 1 recruiting AGastroenterology Orphan designation

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

2 Completed trials

2 Sponsors

7 Countries

Phase III

Phase IV

Phase III: 2 Phase IV: 1

Indications tested

Partial lipodystrophy 2 Congenital generalised lipodystrophy 1

Sponsors using this IMP

Chiesi Farmaceutici S.p.A. 2 Amryt Pharmaceuticals Designated Activity Company 1

All trials

3 total

A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily… Recruiting

2022-502950-14-00 Phase IV 3 countries Chiesi Farmaceutici S.p.A.
A clinical Study to Evaluate Metreleptin Treatment in Subjects with Partial Lipodystrophy over 12-Month Timeframe Ended

2022-501799-24-00 Phase III 4 countries Chiesi Farmaceutici S.p.A.
Open-label study to evaluate metreleptin in children under 6 years of age with generalised lipodystrophy Ended

2022-501781-22-00 Phase III 4 countries Amryt Pharmaceuticals Designated Activity Company

Showing 1–3 of 3 trials

← All drugs A–Z